Rhythm Pharmaceuticals Announces Completion of Evaluation for Enrollment in Setmelanotide Hypothalamic Obesity Trial Phase and Additional Updates
— Primary Phase 3 Knowledge in Hypothalamic Obesity Expected by 1H2025 —- Positive resolution was received for IMCIVREE® (setmelanotide) for tr. . .